Results 51 to 60 of about 13,127 (167)

Favipiravir in Covid-19 [PDF]

, 2020
The SARS-Cov-2 virus, emerged in December 2019 in Wuhan, China and has now spread to all parts of the world. Many research groups are carrying out intense research on drugs and vaccines to treat or prevent Covid-19.
De Zoysa, Ishan, De Mel, Sanjay, Abeysuriya, Visula, L. Seneviratne, Suranjith, Niloofa, Roshan   +4 more
core   +1 more source

Simultaneous Determination of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) and Favipiravir in Human Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus (severe acute respiratory syndrome-related coronavirus 2).
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source

Renal Clearable Luminogenic Reporter for Ultrasensitive Influenza Virus Imaging and Efficient Antiviral Therapies Monitoring in Living Mice

Advanced Science, EarlyView.
A viral luminogenic reporter with chemiluminescence/fluorescence dual‐response and efficient renal clearance was developed for non‐invasive imaging and urinalysis of H1N1 virus protease, allowing for remote detection of H1N1 virus infections and monitoring of antiviral therapeutic efficacy in living mice.
Bankang Ruan, Chudan Liang, Meilin Hu, Weiping Xu, Jingjing Che, Jun Qian, Bingcai Jiang, Linna Liu, Xiancai Ma, Jiaguo Huang   +9 more
wiley   +1 more source

Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
Viral proteins represent key vulnerabilities in human coronaviruses (HCoVs). This review outlines inhibitors targeting spike (S), main protease (Mpro), papain‐like protease (PLpro), and RNA‐dependent RNA polymerase (RdRp), mapping chemically diverse strategies that disrupt entry and replication, and provides an integrated view of current candidates ...
Álvaro de la Cruz‐Potenciano, Miguel Maldonado, María‐José Camarasa, Sonia de Castro   +3 more
wiley   +1 more source

Favipiravir for treating COVID-19. [PDF]

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to challenge the health workforce and societies worldwide.
John, Jisha Sara, Kirubakaran, Richard, Korula, Pritish, Tharyan, Prathap, Rupali, Priscilla, Alexander, Hanna, Singh, Bhagteshwar   +6 more
core   +1 more source

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

Frontiers in Pharmacology, 2021
Background: In addition to supportive therapy, antiviral therapy is an effective treatment for coronavirus disease 2019 (COVID-19).Objective: To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients.Methods ...
Chang Chen, Chang Chen, Yi Zhang, Yi Zhang, Jianying Huang, Jianying Huang, Ping Yin, Zhenshun Cheng, Jianyuan Wu, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Bo Chen, Mengxin Lu, Yongwen Luo, Lingao Ju, Jingyi Zhang, Xinghuan Wang, Xinghuan Wang, Xinghuan Wang, Xinghuan Wang   +21 more
doaj   +1 more source

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

Chemistry – A European Journal, Volume 32, Issue 34, 11 September 2026.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier, Duan Li, Leentje Persoons, Graciela Andrei, Robert Snoeck, Dominique Schols, Lieve Naesens, Xiao Jia   +7 more
wiley   +1 more source

Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice

Frontiers in Pharmacology
Favipiravir, the first RNA polymerase inhibitor approved to treat resistant influenza, has been reported to be associated with central nervous system (CNS) side effects, particularly anxiety-like behavior; nevertheless, the underlying mechanism remains ...
Yuzhou Xiao, Chunqi Liu, Xiaojie Wang, Hongchun Li, Liang Wang, Kun Gou, Xingchen Liu, Xinqi Guan, Xia Zhou, Xiumei He, Yue Zhao, Lei Tao, Xiaodan Pan, Linhong Jiang, Yaxing Chen, Huan Liu, Yanping Dai, Qian Bu, Meng Qin, Ruiming Zhu, Bo Chen, Angelo D. Flores, Yinglan Zhao, Xiaobo Cen   +23 more
doaj   +1 more source

Eugenol‐Derived Piperazine Mannich Bases as Selective Inhibitors of Mayaro Virus: In Vitro Antiviral Evaluation and Mechanistic Insights

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Arboviruses represent an ongoing global health challenge, particularly in tropical regions where diseases caused by Chikungunya virus (CHIKV) and Mayaro virus (MAYV) continue to emerge. Given the absence of licensed antiviral therapies, the identification of effective small molecules remains critical.
Adriana Cotta Cardoso Reis, Amália Luíza de Sousa da Silva, Camila Portruneli, Augusto Vieira Pontes Silva, Saulo Fehelberg Pinto Braga, Igor Rodrigues Lapa, Thiago Belarmino de Souza, Lucas Lopardi Franco, Diogo Teixeira Carvalho, Geraldo Célio Brandão   +9 more
wiley   +1 more source

Çok Tartışılan Bir İlacın Hikayesi; Favipiravir

, 2023
ÖZETAmaç: Koronavirüs hastalığı (Covid-19) pandemisinde favipiravir Sağlık Bakanlığı tarafından tedavi amacıyla ücretsiz olarak dağıtılmıştır. Bu çalışmanın amacı, hastaların favipiraviri kullanma durumları ve buna etki eden faktörlerin araştırılmasıdır ...
Mıstanoğlu Özatağ, Duru, Duru MISTANOĞLU ÖZATAĞ, Durmaz, Adem, Adem DURMAZ   +3 more
core   +1 more source